BRAF and melanoma: Nevertheless, the majority of patients experience secondary resistance in a comparatively short period these medications are very effective for about half of patients with BRAF‐mutated melanomas (Chapman et al. 2011; Rebecca, Sondak, and Smalley 2012; Scolyper, Long, and Thompson 2011).